AstraZeneca Pharma India Limited

NSEI:ASTRAZEN 株式レポート

時価総額:₹187.9b

AstraZeneca Pharma India 過去の業績

過去 基準チェック /16

AstraZeneca Pharma Indiaは、平均年間15.2%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間13.6% 10.6%収益成長率で 成長しています。 AstraZeneca Pharma Indiaの自己資本利益率は13.5%であり、純利益率は6.9%です。

主要情報

15.2%

収益成長率

15.2%

EPS成長率

Pharmaceuticals 業界の成長17.5%
収益成長率10.6%
株主資本利益率13.5%
ネット・マージン6.9%
次回の業績アップデート13 Nov 2024

最近の業績更新

We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Jun 03
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Recent updates

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

Sep 18
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Jun 03
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

May 22
Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Apr 04
We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Nov 10
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Jul 06
AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Jun 16
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Aug 02
Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Feb 25
Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Feb 04
Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Jan 18
Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

Dec 31
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Dec 13
We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Nov 25
Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

Nov 07
Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Oct 20
What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Sep 24
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

Aug 28
If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Aug 02
What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Jul 12
Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

収支内訳

AstraZeneca Pharma India の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NSEI:ASTRAZEN 収益、費用、利益 ( )INR Millions
日付収益収益G+A経費研究開発費
30 Jun 2413,8769592,4960
31 Mar 2412,9551,6152,4740
31 Dec 2311,9701,3932,7090
30 Sep 2311,4101,5282,6330
30 Jun 2310,6611,3302,5670
31 Mar 2310,0309932,6080
31 Dec 229,5021,1002,6470
30 Sep 229,0099212,5520
30 Jun 228,6257152,4830
31 Mar 228,0566162,3450
31 Dec 217,8396092,2790
30 Sep 217,8367052,2310
30 Jun 217,9548492,2360
31 Mar 218,1369332,2270
31 Dec 207,9827562,2450
30 Sep 208,2188132,1960
30 Jun 208,2086932,1760
31 Mar 208,3187222,1960
31 Dec 198,2727252,0700
30 Sep 198,1857492,1040
30 Jun 197,7146961,9980
31 Mar 197,2835452,0610
31 Dec 186,8874781,9560
30 Sep 186,021831,8870
30 Jun 186,0502651,8370
31 Mar 185,7102591,5570
31 Dec 175,3191751,4930
30 Sep 175,5364421,4390
30 Jun 175,2751762,1050
31 Mar 175,4372011,5870
31 Dec 165,8662791,8180
30 Sep 165,8092061,7770
30 Jun 165,7111311,7320
31 Mar 165,637531,7680
31 Dec 155,5294282,8920
30 Sep 155,1662072,9340
30 Jun 154,753-51,5460
31 Mar 154,690-2081,7150
31 Dec 144,624-6152,948103
30 Sep 144,732-4662,906103
30 Jun 144,742-1991,7020
31 Mar 144,737-52,773103
31 Dec 134,545-1652,555164

質の高い収益: ASTRAZENには₹423.4M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が30th June, 2024に影響を及ぼしています。

利益率の向上: ASTRAZENの現在の純利益率 (6.9%)は、昨年(12.5%)よりも低くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ASTRAZENの収益は過去 5 年間で年間15.2%増加しました。

成長の加速: ASTRAZENは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: ASTRAZENは過去 1 年間で収益成長率がマイナス ( -27.9% ) となったため、 Pharmaceuticals業界平均 ( 19.1% ) と比較することが困難です。


株主資本利益率

高いROE: ASTRAZENの 自己資本利益率 ( 13.5% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘